Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.
复制标题

DOI:
10.18632/oncotarget.8031
复制
发表时间:
2016-04-19
期刊:
影响因子:
--
通讯作者:
Davies BR
Davies BR
中科院分区:
其他
文献类型:
--
作者:
Lynch JT;McEwen R;Crafter C;McDermott U;Garnett MJ;Barry ST;Davies BR

文献摘要

参考文献

被引文献

相似文献

选择性磷酸肌醇 3 激酶 (PI3K)/AKT/mTOR 抑制剂目前正在临床研究中进行评估。为了确定对 PI3K 通路抑制剂敏感的肿瘤类型,我们针对癌细胞系组(971 细胞系)筛选了靶向 PI3Kα/δ (AZD8835)、PI3Kβ/δ (AZD8186)、AKT (AZD5363) 和 mTORC1/2 (AZD2014) 的化合物。对 AKT 和 mTOR 抑制敏感的血液恶性肿瘤有很多,其中在 T 细胞急性淋巴细胞白血病 (T-ALL) 中观察到的敏感性最高。我们发现所有 NOTCH 突变 T-ALL 细胞系对 AKT 和 mTORC1/2 抑制剂敏感,对靶向 PI3K α、β 或 δ 亚型的药物仅部分敏感。仅在 PTEN 蛋白缺失和高水平活性 AKT 的细胞系中经过 AKTi 处理后才会诱导细胞凋亡。总之,我们已经证明,T-ALL 细胞系对 PI3K/AKT/mTOR 通路中不同节点的抑制表现出不同的敏感性,并且抑制 AKT 或 mTOR 可能在这种疾病中具有治疗益处。
Selective phosphoinositide 3-kinase (PI3K)/AKT/mTOR inhibitors are currently under evaluation in clinical studies. To identify tumor types that are sensitive to PI3K pathway inhibitors we screened compounds targeting PI3Kα/δ (AZD8835), PI3Kβ/δ (AZD8186), AKT (AZD5363) and mTORC1/2 (AZD2014) against a cancer cell line panel (971 cell lines). There was an enrichment of hematological malignancies that were sensitive to AKT and mTOR inhibition, with the greatest degree of sensitivity observed in T-cell acute lymphoblastic leukemia (T-ALL). We found that all NOTCH mutant T-ALL cell lines were sensitive to AKT and mTORC1/2 inhibitors, with only partial sensitivity to agents that target the PI3K α, β or δ isoforms. Induction of apoptosis only occurred following AKTi treatment in cell lines with PTEN protein loss and high levels of active AKT. In summary, we have demonstrated that T-ALL cell lines show differential sensitivity to inhibition at different nodes in the PI3K/AKT/mTOR pathway and inhibiting AKT or mTOR may have a therapeutic benefit in this disease setting.
DOI: 10.1182/blood-2008-02-137737
发表时间: 2009-02-19
期刊: BLOOD
影响因子: 20.3
作者:
Levy, Dana S.;Kahana, Jason A.;Kumar, Rakesh
通讯作者: Kumar, Rakesh
DOI: 10.1126/scitranslmed.3005747
发表时间: 2013-07-31
影响因子: 17.1
作者:
Elkabets M;Vora S;Juric D;Morse N;Mino-Kenudson M;Muranen T;Tao J;Campos AB;Rodon J;Ibrahim YH;Serra V;Rodrik-Outmezguine V;Hazra S;Singh S;Kim P;Quadt C;Liu M;Huang A;Rosen N;Engelman JA;Scaltriti M;Baselga J
通讯作者: Baselga J
DOI: 10.1038/leu.2013.369
发表时间: 2014-06-01
期刊: LEUKEMIA
影响因子: 11.4
作者:
Lonetti, A.;Antunes, I. L.;Martelli, A. M.
通讯作者: Martelli, A. M.
雷帕霉素使 T-ALL 细胞对地塞米松诱导的细胞凋亡敏感
DOI: 10.1186/1756-9966-29-150
发表时间: 2010-11-18
期刊: Journal of experimental & clinical cancer research : CR
影响因子: --
作者:
Gu L;Zhou C;Liu H;Gao J;Li Q;Mu D;Ma Z
通讯作者: Ma Z
DOI: 10.1158/1535-7163.mct-15-0365
发表时间: 2015-11-01
影响因子: 5.7
作者:
Guichard, Sylvie M.;Curwen, Jon;Cosulich, Sabina C.
通讯作者: Cosulich, Sabina C.